Total Payments
$4,068
2024 Payments
$271.58
Companies
39
Transactions
274
Medicare Patients
4,451
Medicare Billing
$802,820
Payment Breakdown by Category
Food & Beverage$3,784 (93.0%)
Education$283.91 (7.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,784 | 270 | 93.0% |
| Education | $283.91 | 4 | 7.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $597.73 | 48 | $0 (2024) |
| Genentech USA, Inc. | $312.71 | 25 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $308.51 | 22 | $0 (2021) |
| Celgene Corporation | $284.36 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $225.51 | 15 | $0 (2024) |
| GlaxoSmithKline, LLC. | $213.54 | 11 | $0 (2024) |
| Incyte Corporation | $194.29 | 4 | $0 (2021) |
| Amgen Inc. | $187.29 | 8 | $0 (2020) |
| Seattle Genetics, Inc. | $185.32 | 21 | $0 (2019) |
| Eisai Inc. | $141.05 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $271.58 | 14 | GlaxoSmithKline, LLC. ($169.90) |
| 2023 | $65.94 | 4 | Bayer Healthcare Pharmaceuticals Inc. ($20.86) |
| 2022 | $129.97 | 9 | Daiichi Sankyo Inc. ($45.40) |
| 2021 | $368.09 | 22 | Incyte Corporation ($77.99) |
| 2020 | $336.94 | 24 | E.R. Squibb & Sons, L.L.C. ($76.97) |
| 2019 | $931.54 | 67 | Janssen Biotech, Inc. ($147.14) |
| 2018 | $1,065 | 68 | Celgene Corporation ($138.87) |
| 2017 | $899.00 | 66 | E.R. Squibb & Sons, L.L.C. ($311.66) |
All Payment Transactions
274 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.48 | General |
| Category: Hematology | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $4.31 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $5.00 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.67 | General |
| Category: Hematology | ||||||
| 07/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $3.35 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 06/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $2.91 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $16.66 | General |
| Category: Oncology | ||||||
| 05/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $114.41 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $2.59 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: ONCOLOGY | ||||||
| 01/22/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: ONCOLOGY | ||||||
| 10/27/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 03/21/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: VACCINES | ||||||
| 03/16/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.84 | General |
| Category: Hematology | ||||||
| 02/16/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/22/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Oncology | ||||||
| 12/01/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Hematology | ||||||
| 10/28/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $12.80 | General |
| Category: Hematology | ||||||
| 10/13/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/14/2022 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Iron Deficiency Anemia | ||||||
| 07/28/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,046 | 2,493 | $1.2M | $219,684 |
| 2022 | 9 | 1,079 | 2,705 | $1.0M | $198,787 |
| 2021 | 9 | 1,153 | 2,997 | $1.0M | $218,850 |
| 2020 | 11 | 1,173 | 2,474 | $554,060 | $165,500 |
Total Patients
4,451
Total Services
10,669
Medicare Billing
$802,820
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 307 | 1,089 | $614,121 | $111,909 | 18.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 133 | 289 | $141,047 | $28,762 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 66 | 147 | $116,427 | $22,381 | 19.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 93 | 105 | $85,831 | $15,299 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 175 | $98,796 | $14,073 | 14.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 119 | $44,683 | $7,956 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $42,560 | $7,893 | 18.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 43 | $33,979 | $4,570 | 13.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 190 | 424 | $5,088 | $3,553 | 69.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 30 | $12,004 | $2,110 | 17.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 23 | 28 | $5,104 | $1,178 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 321 | 1,142 | $603,716 | $121,014 | 20.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 114 | 252 | $111,742 | $21,895 | 19.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 69 | 170 | $88,772 | $13,624 | 15.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 64 | 65 | $56,154 | $10,780 | 19.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 48 | 48 | $45,537 | $9,058 | 19.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 93 | 149 | $45,886 | $8,962 | 19.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 50 | $36,707 | $7,789 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 34 | $13,295 | $2,544 | 19.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 276 | 768 | $8,877 | $2,272 | 25.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 22 | 27 | $4,511 | $848.38 | 18.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 322 | 1,151 | $544,832 | $123,615 | 22.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 123 | 293 | $129,031 | $25,998 | 20.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 80 | 257 | $121,280 | $21,492 | 17.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 67 | 68 | $58,154 | $11,698 | 20.1% |
About Dr. Patrick Lee, MD
Dr. Patrick Lee, MD is a Hematology & Oncology healthcare provider based in West Long Branch, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356442602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Lee, MD has received a total of $4,068 in payments from pharmaceutical and medical device companies, with $271.58 received in 2024. These payments were reported across 274 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($3,784).
As a Medicare-enrolled provider, Lee has provided services to 4,451 Medicare beneficiaries, totaling 10,669 services with total Medicare billing of $802,820. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location West Long Branch, NJ
- Active Since 09/26/2006
- Last Updated 05/01/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356442602
Products in Payments
- OPDIVO (Biological) $394.37
- ADCETRIS (Biological) $214.19
- DARZALEX (Biological) $174.99
- OJJAARA (Drug) $152.75
- Herceptin (Biological) $105.28
- REBLOZYL (Biological) $86.64
- TASIGNA (Drug) $77.49
- Halaven (Drug) $70.70
- Lenvima (Drug) $70.35
- INJECTAFER (Drug) $68.98
- Stivarga (Drug) $67.84
- VERZENIO (Drug) $66.81
- Venclexta (Drug) $62.13
- JADENU (Drug) $60.22
- NINLARO (Drug) $58.09
- PROMACTA (Drug) $52.10
- SUTENT (Drug) $51.98
- KISQALI (Drug) $48.98
- Perjeta (Biological) $48.92
- Avastin (Biological) $47.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.